The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R01 | Nasal preparations | |
| 3 | R01A | Decongestants and other nasal preparations for topical use | |
| 4 | R01AA | Sympathomimetics, plain | |
| 5 | R01AA05 | Oxymetazoline |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| NASAL - Nasal | 0.4 mg |
| Active Ingredient | Description | |
|---|---|---|
| Oxymetazoline |
Oximetazoline is an imidazoline derivative. It exhibits sympathomimetic activity and specifically stimulates the α-adrenergic receptors of the sympathetic system. When administered topically to the nose it causes vasoconstriction of the expansed arterioles of the mucosal nose and a concurrent reduction in blood flow. It also reduces the hypersecretion of the nasal mucosa, ultimately contributing to the decongestion of the nasal mucosa. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| UTABON ADULTS Nasal spray, solution | Medicines Authority (MT) | MPI, EU: SmPC | |
| UTABON PEDIATRIC Nasal drops, solution | Medicines Authority (MT) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
